Osteopontin expression in lung cancer

Lung Cancer

Volumn 15, Issue 3, 1996, Pages 311-323

  Chambers, Ann F ^a,b   Wilson, Sylvia M ^a   Kerkvliet, Nancy ^c   O'Malley, Frances P ^b,c   Harris, John F ^a,b   Casson, Alan G ^d  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

immunohistochemistry; integrin binding proteins; lung carcinoma; osteopontin; RNA; tumor markers

Indexed keywords

MESSENGER RNA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030297877     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(95)00595-1     Document Type: Article

References (26)

1. [1] Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF. Inhibition of RGD-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994; 269: 23280-23285.
2. [2] Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994; 54: 832-837.
3. [3] Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95-100.
4. [4] Boring CC, Squires TS, Tong T. Cancer Statistics, 1993. CA Cancer J Clin 1993; 43: 7-26.
5. [5] Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi E, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-623.
6. [6] Butler WT. The nature and significance of osteopontin. Connective Tissue Res 1989; 23: 123-136.
7. [7] Chambers AF, Behrend EI, Wilson SM, Denhardt DT. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res 1992; 12: 43-48.
8. [8] Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg AH, Wright JA, McLeod M, Denhardt DT. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 1990; 46: 133-137.
9. [9] Craig AM, Nemir M, Mukherjee BB, Chambers AF, Denhardt DT. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: Enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun 1988; 157: 166-173.
10. [10] Denhardt DT, Butler WT, Chambers AF, Senger DR, editors. Osteopontin: role in cell signalling and adhesion. Ann N Y Acad Sci 1995; 760: 388.
11. [11] Denhardt DT, Chambers AF. Overcoming obstacles to metastasis - defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994; 56: 48-51.
12. [12] Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-1482.
13. [13] Gardner HAR, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994; 9: 2321-2326.
14. [14] Gazdar AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 1992; 69: 1592-1599.
15. [15] Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with metastatic potential. Mol Cell Biol 1995; 15: 476-487.
16. [16] Hirota S, Ito A, Nagoshi J, Takeda M. Kurata A, Takatsuka Y, Kohri K, Nomura S, Kitamura Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995; 72: 64-69.
17. [17] Maniatis T, Frisch EF, Sambrook J. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982.
18. [18] Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993; 103(Suppl): 449s-456s.
19. [19] Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993; 13: 225-246.
20. [20] Roth JA. Molecular events in lung cancer. Lung Cancer 1995; 12 (Suppl 2): S3-S15.
21. [21] Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989; 9: 1291-1299.
22. [22] Su L, Mukherjee AB, Mukherjee BB. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of JB6 epidermal cells. Oncogene 1995; 10: 2163-2169.
23. [23] Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1994; 75: 191-202.
24. [24] Xuan JW, Hota C, Chambers AF. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994; 54: 247-255.
25. [25] Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995; 57: 680-690.
26. [26] Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990; 7: 491-502.